-
2024-516849-39-01
5
antibiotic therapy in Sepsis
-
2024-517621-54-00
5
High-risk non-muscle invasive bladder cancer (NMIBC) after transurethr
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2025-523683-20-00
4
Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2023-508056-19-00
5
2025-10-02
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
-
2023-504254-35-00
7
2023-06-20
Unresectable locally advanced or metastatic solid tumors:
• Clear cell
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2024-519208-29-00
4
2026-04-02
Pleural mesothelioma
-
2025-521859-23-00
9
2026-03-31
PSMA-positive mCRPC with prior exposure to at least one prior ARPI
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2025-522169-31-00
4
2025-10-30
Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, co
-
2024-520051-24-00
4
2025-09-30
Breast cancer
-
2023-510333-28-00
5
2025-08-20
Uveal Melanoma
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2024-515349-41-00
4
2025-07-29
Metastatic Breast Cancer HR+, HER2-
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela